REDWOOD CITY, Calif.,
Nov. 19, 2018 /PRNewswire/ -- Genomic
Health, Inc. (NASDAQ: GHDX) today announced that it will present
results from two large studies of the Oncotype DX Breast Recurrence
Score® test at the 2018 San Antonio Breast Cancer
Symposium® (SABCS), which will be held December 4-8. The study findings reinforce the
value of the Oncotype DX® test in optimizing treatment
and outcomes in patients with both node-negative and node-positive
early-stage breast cancer. Presentations include:
- Results from a large population-based clinical outcomes study
based on the Surveillance, Epidemiology, and End Results (SEER)
registry program of the National Cancer Institute (NCI), the
premier source of cancer statistics in the United States. To provide long-term (nine
years) real-world evidence for both prognosis and chemotherapy
benefit, the study assessed breast cancer-specific survival in
patients with node-negative and node-positive disease who were
treated based on their Oncotype DX Breast Recurrence Score test
results.
- Analysis of 500 early-stage breast cancer patients age 40 or
younger to further the understanding of the value of the Oncotype
DX test in guiding chemotherapy treatment decisions. The analysis
is based on a multi-center prospective cohort study led by
Dana-Farber Cancer Institute investigators in Boston.
Complete results from both studies will be announced in
accordance with the SABCS embargo policy. Following are details for
the two poster presentations:
- Abstract: P3-11-02
Poster: Breast cancer specific mortality in patients with
node-negative and node-positive breast cancer guided by the 21-gene
assay: A SEER-genomic population-based study
Authors: Hortobagyi GN, Shak S, Sledge GW Jr., Winer EP, Albain KS,
Mamounas EP, Jakubowski DM, Petkov VI, Wolmark N
Location: Hall 1
Date and Time: Thursday, December 6,
7-9 a.m. CST
- Abstract: P2-08-07
Poster: Prognostic impact of the 21-gene Recurrence Score assay
among young women with node-negative and node-positive early-stage
breast cancer
Authors: Poorvu PD, Gelber SI, Rosenberg SM, Ruddy KJ, Tamimi RM,
Collins LC, Peppercorn J, Schapira L, Borges VF, Come SE, Warner E,
Jakubowski DM, Russell C, Winer EP, Partridge AH
Location: Hall 1
Date and Time: Thursday, December 6,
7-9 a.m. CST
About Oncotype DX®
The Oncotype
DX® portfolio of breast, colon and prostate cancer
tests applies advanced genomic science to reveal the unique biology
of a tumor in order to optimize cancer treatment decisions. The
company's flagship product, the Oncotype DX breast cancer test, has
been shown to predict the likelihood of chemotherapy benefit as
well as recurrence in invasive breast cancer. Additionally, the
test predicts the likelihood of recurrence in a pre-invasive form
of breast cancer called DCIS. With more than 950,000 patients
tested in more than 90 countries, the Oncotype DX tests have
redefined personalized medicine by making genomics a critical part
of cancer diagnosis and treatment. To learn more
about Oncotype DX tests, visit www.OncotypeDX.com or
www.MyBreastCancerTreatment.org.
About Genomic Health
Genomic Health, Inc.
(NASDAQ: GHDX) is the world's leading provider of genomic-based
diagnostic tests that help optimize cancer care, including
addressing the overtreatment of the disease, one of the greatest
issues in healthcare today. With its Oncotype
IQ® Genomic Intelligence Platform, the company is
applying its world-class scientific and commercial expertise and
infrastructure to lead the translation of clinical and genomic big
data into actionable results for treatment planning throughout the
cancer patient journey, from diagnosis to treatment selection and
monitoring. The Oncotype IQ portfolio of genomic tests and services
currently consists of the company's flagship line of Oncotype
DX® gene expression tests that have been used to
guide treatment decisions for more than 950,000 cancer patients
worldwide. Genomic Health is expanding its test portfolio
to include additional liquid- and tissue-based tests, including the
recently launched Oncotype DX® AR-V7 Nucleus
Detect™ test. The company is based in Redwood City, California, with
international headquarters in Geneva, Switzerland. For
more information, please visit, www.GenomicHealth.com and
follow the company on
Twitter: @GenomicHealth, Facebook, YouTube and LinkedIn.
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements are subject to risks and
uncertainties that could cause actual results to differ materially,
and reported results should not be considered as an indication of
future performance. These risks and uncertainties include, but are
not limited to: our business model; the applicability of clinical
study results to actual outcomes; the impact of results from
clinical studies on market adoption of Oncotype DX tests;
unanticipated costs or delays in research and development efforts;
and other risks and uncertainties set forth in our filings with the
Securities and Exchange Commission, including our most recent
report on Form 10-Q for the quarter ended September 30, 2018. These forward-looking
statements speak only as of the date hereof. Genomic Health
disclaims any obligation to update these forward-looking
statements.
NOTE: The Genomic Health logo, Oncotype, Oncotype
DX, Breast Recurrence Score, DCIS Score, Genomic Prostate Score,
Oncotype DX AR-V7 Nucleus Detect, and Oncotype IQ are trademarks or
registered trademarks of Genomic Health, Inc. All other
trademarks and service marks are the property of their respective
owners.
GHDX-B
View original content to download
multimedia:http://www.prnewswire.com/news-releases/genomic-health-announces-presentation-of-two-large-studies-at-the-2018-san-antonio-breast-cancer-symposium-reinforcing-real-world-value-of-the-oncotype-dx-breast-recurrence-score-test-300752477.html
SOURCE Genomic Health, Inc.